Course Information

Release date: December 12, 2025
Expiration date: December 12, 2026
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

PROGRAM OVERVIEW

Over the past decade, breakthroughs in understanding chronic rhinosinusitis with nasal polyps (CRSwNP) have revealed its complexity and the pivotal role of airway epithelial cells in driving inflammation. Alarmin cytokines thymic stromal lymphopoietin (TSLP), interleukin (IL)-25, and IL-33, released upon epithelial injury, trigger and amplify both type 1 and type 2 inflammatory responses. Unlike existing biologics that target downstream type 2 pathways, innovative anti-alarmin therapies act upstream, offering promise for patients across inflammatory profiles. As these therapies have begun to receive FDA approval, clinicians must stay informed to navigate this evolving treatment landscape. Join us for an engaging, expert-led program exploring the science behind alarmins, emerging clinical trial data, and practical guidance on integrating these groundbreaking therapies into practice.

Learning Objectives

TARGET AUDIENCE

This educational activity has been designed to meet the needs of allergy/immunology specialists, rhinologists, advanced practice providers, and other healthcare providers involved in the evaluation and treatment of patients with CRSwNP.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Evaluate the efficacy of current treatments and therapies for CRSwNP and unmet needs of patients with inadequate response to these agents
Explain the role of epithelial cytokines in the immunopathogenesis of CRSwNP and their contribution to disease heterogeneity
Incorporate current clinical trial evidence into treatment plans for initiating, sequencing, and monitoring the use of biologic therapies in CRSwNP
Develop individualized, multidisciplinary treatment strategies for patients with CRSwNP and coexisting airway diseases

Faculty Information and Disclosures

FACULTY

	Joseph K. Han, MD Professor of Medicine Vice Chair of Department of Otolaryngology – Head and Neck Surgery Old Dominion University Norfolk, Virginia
	Stella Lee, MD Section Chief – Rhinology Associate Professor, Harvard Medical School Brigham and Women’s Hospital Boston, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Joseph K. Han, MD

Research Consultant: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi

Stella Lee, MD

Advisory Boards: AstraZeneca, Diceros Therapeutics, Genentech, GlaxoSmithKline, Lyra Therapeutics, Optinose, Regeneron, Sanofi

Clinical Trial Funding: AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, Optinose, Regeneron, Sanofi

Equity: Diceros Therapeutics

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 12, 2025 through December 12, 2026, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will issued by our system and immediately available for download upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you register or participate in an educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and… (continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required

For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: December 12, 2025Expiration date: December 12, 2026Estimated time to complete activity: 45 minutes

A New Target in Sight: Alarmin Cytokines and the Evolving Biologic Landscape in CRSwNP